'Oxaliplatin' diaporamas de présentation

C Loprinzi P Atherton R Qin D Seisler S Dakhil R Qamar

Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity, N08CB An Alliance for Clinical Trials in Oncology Study. C Loprinzi P Atherton R Qin D Seisler S Dakhil R Qamar

464 views • 33 slides

Ali Shamsedddine, MD Professor of Medicine Head of Hematology-Oncology Division

No Effect on Tumor Response with Weekly Oxaliplatin Added to Standard Preoperative 5-FU/RT in locally Advanced Rectal Cancer. Ali Shamsedddine, MD Professor of Medicine Head of Hematology-Oncology Division American University of Beirut Medical Center. Challenges in treatment of rectal Cancer.

341 views • 24 slides

Management of Colorectal Liver Metastasis

Management of Colorectal Liver Metastasis. Joint Hospital Grand Round Dr. Edgar Lau Department of Surgery, PYNEH 12/1/2008. Background. Liver metastasis is most frequently seen in patient with colorectal carcinoma 15-25% present at the time of diagnosis

595 views • 23 slides

XENOX

XENOX.

334 views • 23 slides

424 views • 22 slides

Lighting the way with XELOX (Xeloda plus oxaliplatin)

499 views • 22 slides

Background

The Combination of Bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) is highly active in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604).

335 views • 18 slides

Background

330 views • 17 slides

338 views • 17 slides

Combination and Sequential Chemotherapy of Metastatic Colorectal Cancer

Combination and Sequential Chemotherapy of Metastatic Colorectal Cancer. Daniel G. Haller, MD University of Pennsylvania Cancer Center. Discussion topics. What is the goal of administering combination vs sequential therapy? What is the evidence for combination versus sequential therapy?

422 views • 11 slides

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer NEJM January 3, 2008

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer NEJM January 3, 2008. Authors: David Cunningham et al Date posted: April 3, 2008. Treatment A: ECF Epirubicin 50 mg/m2 IV q 3 weeks Cisplatin 60 mg/m2 IV q 3 weeks 5-FU 200 mg/m2 per day continuous infusion. Treatment B: ECX

220 views • 5 slides

World Oxaliplatin Industry Research & Forecasts Report 2020

158 views • 5 slides

CPT

158 views • 1 slides